2型糖尿病患者接受减重手术后医疗支出下降
这项回顾性队列研究纳入6,690例接受减重手术的肥胖2型糖尿病患者与19,122例匹配的非手术患者,比较术前3年至术后5.5年的总支出、门诊、住院及药物支出。手术患者自术后1年起至5.5年总支出显著低于对照组,主要归因于药物支出下降56%,但术后住院概率更高。
要点
- 术后5.5年手术患者每6个月总支出较对照组低566美元(95%CI -807至-316)。
- 手术患者药物支出从术前6个月的2,204美元降至术后5.5年的每6个月969美元,降幅56%。
- 手术患者术后每6个月住院概率为4.0-6.5%,高于对照组的2.4-3.1%。
核心结论
- 接受减重手术的2型糖尿病患者术后总支出显著低于匹配对照患者,主要因药物支出大幅下降。
- 鉴于糖尿病药物治疗费用快速上升,减重手术相关的长期费用节省可能进一步增加。
研究设计与样本
- 回顾性队列研究,纳入2012-2019年接受减重手术的6,690例肥胖2型糖尿病患者和19,122例匹配的非手术患者。
- 采用广义估计方程比较术前3年至术后5.5年的总支出、门诊支出、住院支出和药物支出,支出按6个月区间估算。
主要发现
- 手术组与非手术组匹配良好:女性73%,平均BMI 44 kg/m2,平均年龄50岁,32%使用胰岛素。
- 术前1年内两组估算总支出相似;手术患者自术后1年起至术后5.5年总支出显著低于对照组,术后5.5年每6个月低566美元(95%CI -807至-316)。
- 支出差异主要归因于手术患者药物支出下降56%,从术前6个月的2,204美元降至术后5.5年的每6个月969美元。
- 手术患者整个术后期间住院概率更高,每6个月为4.0-6.5%,对照组为2.4-3.1%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Bariatric surgery lowers the risk of developing microvascular and macrovascular complications of type 2 diabetes, but it is unclear whether it also lowers long-term health expenditures in this population. RESEARCH DESIGN AND METHODS: In a retrospective cohort study of 6,690 patients with obesity and type 2 diabetes who underwent bariatric surgery in 2012-2019 and 19,122 matched nonsurgical patients, we compared total, outpatient, inpatient, and medication expenditures 3 years presurgery and 5.5 years postsurgery, using generalized estimating equations. Expenditures were estimated in 6-month intervals. RESULTS: Surgical and nonsurgical cohorts were well-matched, with 73% female, average BMI 44 kg/m2, mean age 50 years, and 32% on insulin. Estimated total expenditures were similar between surgical and nonsurgical patients up to 1 year presurgery. Total expenditures were significantly lower for surgical patients starting 1 year postsurgery and up to 5.5 years postsurgery compared with control patients ($566 lower per 6-month interval at 5.5 years; 95% CI -$807, -$316). Expenditure differences were largely attributable to a 56% drop in medication expenditures for surgical patients, from $2,204 in the 6 months presurgery to $969 per 6-month interval at 5.5 years postsurgery. Surgical patients had a higher probability of inpatient admission throughout the postsurgical period (4.0-6.5% vs. 2.4-3.1% per 6-month interval). CONCLUSIONS: Patients with type 2 diabetes undergoing bariatric surgery have significantly lower total postsurgical expenditures than matched control patients, primarily because of substantial reductions in pharmacy expenditures. The long-term cost savings associated with bariatric surgery are likely to increase further, given the rapidly escalating costs of diabetes pharmacotherapy.
引用
- Sloan CE, Zepel L, Smith VA, et al. Health Expenditures Decline After Bariatric Surgery for Patients With Type 2 Diabetes. Diabetes Care. 2025. PMID: 40504938. doi:10.2337/dc25-0254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。